Redesign Science
0 followers
?
Redesign Science develops and applies a molecular dynamics-driven platform for in silico drug discovery against emerging drug target classes. We work in partnership with Biotech and Pharma to co-develop novel small molecule therapeutics.
Industries
Headquarters
Employees
Links
Org chart
David Rooklin
Collapse
Andrew Avorn
General Counsel
Brian Petkov
VP Methodology
Sharon Blaettler
Head Of Biology
Scott Liu
Director of Business Development
Janan Zhu
Head of Engineering
